Ankyra Therapeutics Doses First Patient in Phase 1b LANTERN Trial Evaluating Tolododekin Alfa With PD-1/PD-L1 Checkpoint Inhibitors in NSCLC

Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint bl...

November 18, 2025 | Tuesday | News
Legend Biotech Expands U.S. R&D Footprint With New Philadelphia Innovation Center

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy,  announced the official opening and ribbon c...

November 17, 2025 | Monday | News
AtomVie and Ariceum Achieve First Clinical Dosing of 225Ac-SSO110 in SANTANA-225 Trial

  AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced that it has successfully supplied the first dose of Ariceum The...

November 13, 2025 | Thursday | News
Pixelgen Technologies and Carolina Molecular Partner to Bring 3D Protein Interactomics to U.S. Researchers

Carolina Molecular Inc., a leading molecular testing services laboratory, and Pixelgen Technologies AB announced  a partnership to expand access to ...

November 13, 2025 | Thursday | News
Daiichi Sankyo Taps General Proximity’s OmniTAC™ Platform to Unlock New Frontiers in Oncology Drug Discovery

The collaboration will leverage General Proximity's OmniTAC™ platform to identify and advance next generation induced proximity agents for...

November 13, 2025 | Thursday | News
GenomOncology Technology Enables Rapid Launch of Glioblastoma Foundation Genomic Testing Lab

GenomOncology announced a strategic partnership with the Glioblastoma Foundation to transform genomic testing for the nation's most aggressive brain canc...

November 12, 2025 | Wednesday | News
Gnome Sciences Identifies Cancer Drug That Prevented ALS in Preclinical Study

Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS (amyotrophic ...

November 12, 2025 | Wednesday | News
Boehringer Ingelheim Receives FDA National Priority Voucher for HERNEXEOS® in First-Line HER2-Mutant NSCLC

  The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® (zongertinib tablets...

November 10, 2025 | Monday | News
Normunity Doses First Patient in Phase 1 Trial of NRM-823, a First-in-Class T Cell Engager

Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastat...

November 06, 2025 | Thursday | News
CARsgen Reports Promising Early Clinical Data for Allogeneic CAR-T Candidates CT0596 and CT1190B in Multiple Myeloma and Lymphoma

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for...

November 04, 2025 | Tuesday | Reports
Moleculin Biotech Expands Global IP Protection With New Australian Patent for Novel Annamycin Formulation

Moleculin Biotech, Inc., a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infecti...

November 03, 2025 | Monday | News
N2OFF Completes Merger with MitoCareX Bio to Expand into Cancer Drug Discovery Targeting Mitochondrial Proteins

N2OFF, Inc. a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced the closing of the ...

October 31, 2025 | Friday | News
IN8bio Adds The Ohio State University as New Clinical Site for INB-100 Phase 1 Trial

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune dise...

October 30, 2025 | Thursday | News
bioAffinity Technologies Secures Australian Patent Expanding Global Lung Health Portfolio

Australian patent strengthens global patent portfolio -bioAffinity Technologies, Inc. a biotechnology company advancing early-stage diagnostic...

October 30, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close